Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2019-07-29 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
公司章程修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table showing amendments to the company's Articles of Association (公司章程修订对照表). It includes specific changes to registered capital, share numbers, business scope, share repurchase conditions, shareholder meeting procedures, board of directors' powers, and committee rules. The document is dated July 30, 2019, and signed by the Board of Directors. It does not contain financial statements or earnings data, nor is it a transcript or announcement of voting results. Instead, it is a governance-related document detailing internal company rules and structural changes to the corporate charter. Therefore, it fits best under Governance Information (CGR). The document length (6689 characters) supports it being a full governance report rather than a brief announcement.
2019-07-29 Chinese
独立董事关于相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion letter regarding various company matters such as related party transactions, external guarantees, use of raised funds, changes in financial statement formats, cash management, and a subsidiary capital reduction proposal. It references compliance with regulatory guidelines and company bylaws but does not contain financial statements or detailed financial data. The document is relatively short (1177 characters) and serves as an opinion or certification rather than a full report. It does not fit categories like Annual Report, Interim Report, or Audit Report. It is not a regulatory announcement or voting result. The content aligns best with a Regulatory Filing (RNS) as it is a formal regulatory disclosure of independent directors' opinions on corporate governance and related matters without substantive financial data or report content.
2019-07-29 Chinese
关于2019年半年度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (332 characters) from a company about the disclosure of its 2019 semi-annual report. It states that the 2019 half-year report and its summary have been disclosed on the official information disclosure website. The document does not contain the actual financial data or the report itself but is a notice informing investors about the availability of the report elsewhere. According to the 'MENU VS MEAL' rule, such a short document that announces the publication of a report without including the report itself should be classified as a Report Publication Announcement (RPA).
2019-07-29 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about the progress and status of using idle raised funds for cash management, including specifics on financial products purchased, redemption details, risk control measures, and approvals. It is not a full financial report like an Annual or Interim Report, nor is it a brief earnings release or a management discussion. The document is a regulatory announcement about financing activities related to the use of idle raised funds for cash management, including investment in financial products and related approvals. It fits best under Capital/Financing Update (CAP) as it provides updates on the company's financing activities and capital management.
2019-07-18 Chinese
2019年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2019 half-year performance forecast (业绩预告) for the period January 1 to June 30, 2019. It provides estimated financial results including revenue and net profit growth percentages, but explicitly states that the forecast is unaudited and preliminary. It also mentions that the actual detailed data will be disclosed in the 2019 half-year report. The document is short (1298 characters) and serves as an earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not a full interim report with audited financial statements. Therefore, the correct classification is Earnings Release (ER). H1 2019
2019-07-14 Chinese
关于与LOXO ONCOLOGY,INC.（礼来制药子公司）达成靶向药物临床研究合作的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a clinical research cooperation agreement between the company and LOXO ONCOLOGY, INC. It details the nature of the collaboration, the parties involved, and the expected impact on the company. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is relatively short (2060 characters) and serves as a formal disclosure of a business cooperation event rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory compliance filing or certification either. The content aligns best with a general regulatory announcement about a material business cooperation, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2019-06-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.